CTMX · Categories · Form 4

CTMX - SEC Form 4 insider transactions

CytomX Therapeutics Inc. (CTMX) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for CTMX

• 81d
  SEC Form 4 filed by Chu Yu-Waye

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 81d
  SEC Form 4 filed by Mccarthy Sean A.

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 81d
  SEC Form 4 filed by Belvin Marcia

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 81d
  SEC Form 4 filed by Ogden Christopher

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 124d
  Chief Business Officer Lester Rachael was granted 20,000 shares (SEC Form 4)

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 124d
  Chief Medical Officer Chu Yu-Waye was granted 75,000 shares, increasing direct ownership by 55% to 210,725 units (SEC Form 4)

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 124d
  SVP, Chief Scientific Officer Belvin Marcia was granted 60,000 shares, increasing direct ownership by 22% to 332,252 units (SEC Form 4)

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 124d
  Chief Financial Officer Ogden Christopher was granted 90,000 shares, increasing direct ownership by 40% to 316,271 units (SEC Form 4)

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 124d
  CEO Mccarthy Sean A. was granted 210,000 shares, increasing direct ownership by 21% to 1,197,891 units (SEC Form 4)

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 210d
  CEO Mccarthy Sean A. sold $461,906 worth of shares (101,793 units at $4.54), decreasing direct ownership by 9% to 987,891 units (SEC Form 4)

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 222d
  SEC Form 4 filed by Chief Business Officer Lester Rachael

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 251d
  SEC Form 4 filed by CEO Mccarthy Sean A.

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 251d
  SEC Form 4 filed by Chief Medical Officer Chu Yu-Waye

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 251d
  SEC Form 4 filed by Chief Financial Officer Ogden Christopher

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 251d
  SEC Form 4 filed by SVP, Chief Scientific Officer Belvin Marcia

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 356d
  Chief Financial Officer Ogden Christopher sold $33,381 worth of shares (12,255 units at $2.72) and converted options into 37,500 shares, increasing direct ownership by 13% to 226,271 units (SEC Form 4)

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 356d
  SVP, Chief Scientific Officer Belvin Marcia converted options into 37,500 shares and sold $37,334 worth of shares (13,884 units at $2.69), increasing direct ownership by 9% to 272,252 units (SEC Form 4)

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 356d
  CEO Mccarthy Sean A. converted options into 150,000 shares and sold $149,264 worth of shares (55,511 units at $2.69), increasing direct ownership by 9% to 1,089,684 units (SEC Form 4)

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 360d
  SEC Form 4 filed by Director Su Zhen

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 360d
  SEC Form 4 filed by Director Young Matthew P.

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 360d
  SEC Form 4 filed by Director Mohindru Mani

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 360d
  SEC Form 4 filed by Director Meyers James R

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 360d
  SEC Form 4 filed by Director Jones Elaine V

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 360d
  SEC Form 4 filed by Director Gilbert Halley E

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 360d
  SEC Form 4 filed by Director Ashworth Alan

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 445d
  CEO Mccarthy Sean A. sold $22,556 worth of shares (37,656 units at $0.60), decreasing direct ownership by 4% to 995,195 units (SEC Form 4)

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 445d
  Chief Financial Officer Ogden Christopher sold $5,122 worth of shares (8,551 units at $0.60), decreasing direct ownership by 4% to 201,026 units (SEC Form 4)

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 445d
  Chief Medical Officer Chu Yu-Waye sold $2,411 worth of shares (4,025 units at $0.60), decreasing direct ownership by 3% to 135,725 units (SEC Form 4)

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 445d
  General Counsel Rowland Lloyd A sold $6,112 worth of shares (10,203 units at $0.60), decreasing direct ownership by 8% to 120,594 units (SEC Form 4)

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 445d
  SVP, Chief Scientific Officer Belvin Marcia sold $11,688 worth of shares (19,512 units at $0.60), decreasing direct ownership by 7% to 248,636 units (SEC Form 4)

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 483d
  Amendment: SVP, Chief Scientific Officer Belvin Marcia was granted 92,500 shares, increasing direct ownership by 53% to 268,148 units (SEC Form 4)

  4/A - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 487d
  SVP, Chief Scientific Officer Belvin Marcia was granted 87,500 shares, increasing direct ownership by 50% to 263,148 units (SEC Form 4)

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 487d
  Chief Medical Officer Chu Yu-Waye was granted 113,500 shares, increasing direct ownership by 432% to 139,750 units (SEC Form 4)

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 487d
  Chief Financial Officer Ogden Christopher was granted 101,500 shares, increasing direct ownership by 94% to 209,577 units (SEC Form 4)

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 487d
  CEO Mccarthy Sean A. was granted 375,000 shares, increasing direct ownership by 57% to 1,032,851 units (SEC Form 4)

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 655d
  Chief Business Officer Landau Jeffrey B converted options into 11,250 shares and sold $5,139 worth of shares (4,181 units at $1.23), increasing direct ownership by 6% to 119,056 units (SEC Form 4)

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 655d
  SVP, Chief Scientific Officer Belvin Marcia converted options into 11,250 shares and sold $5,139 worth of shares (4,181 units at $1.23), increasing direct ownership by 4% to 175,648 units (SEC Form 4)

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 655d
  General Counsel Rowland Lloyd A converted options into 11,250 shares and sold $5,139 worth of shares (4,181 units at $1.23), increasing direct ownership by 6% to 130,797 units (SEC Form 4)

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 655d
  Chief Financial Officer Ogden Christopher sold $2,439 worth of shares (1,984 units at $1.23) and converted options into 6,875 shares, increasing direct ownership by 5% to 108,077 units (SEC Form 4)

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 655d
  CEO Mccarthy Sean A. converted options into 37,500 shares and sold $17,082 worth of shares (13,898 units at $1.23), increasing direct ownership by 4% to 657,851 units (SEC Form 4)

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 724d
  Chief Financial Officer Ogden Christopher was granted 17,500 shares, increasing direct ownership by 20% to 103,186 units (SEC Form 4)

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 752d
  SEC Form 4 filed by Young Matthew P.

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 752d
  SEC Form 4 filed by Su Zhen

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 752d
  SEC Form 4 filed by Mohindru Mani

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 752d
  SEC Form 4 filed by Meyers James R

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 752d
  SEC Form 4 filed by Jones Elaine V

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 752d
  SEC Form 4 filed by Gilbert Halley E

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 752d
  SEC Form 4 filed by Ashworth Alan

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 802d
  Mccarthy Sean A. exercised 109,768 shares at a strike of $1.57, increasing direct ownership by 21% to 634,249 units (SEC Form 4)

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 808d
  SEC Form 4 filed by Su Zhen

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 809d
  Rowland Lloyd A sold $10,986 worth of shares (5,268 units at $2.09), decreasing direct ownership by 4% to 117,728 units (SEC Form 4)

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 809d
  Ogden Christopher sold $6,196 worth of shares (2,971 units at $2.09), decreasing direct ownership by 3% to 85,686 units (SEC Form 4)

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 809d
  Belvin Marcia sold $26,684 worth of shares (12,795 units at $2.09), decreasing direct ownership by 7% to 168,579 units (SEC Form 4)

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 809d
  Mccarthy Sean A. sold $42,175 worth of shares (20,223 units at $2.09), decreasing direct ownership by 4% to 524,481 units (SEC Form 4)

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 809d
  Landau Jeffrey B sold $13,685 worth of shares (6,562 units at $2.09), decreasing direct ownership by 6% to 110,060 units (SEC Form 4)

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 871d
  Mccarthy Sean A. was granted 90,000 shares, increasing direct ownership by 20% to 544,704 units (SEC Form 4)

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 871d
  Rowland Lloyd A was granted 25,000 shares, increasing direct ownership by 26% to 122,996 units (SEC Form 4)

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 871d
  Ogden Christopher was granted 40,000 shares, increasing direct ownership by 82% to 88,657 units (SEC Form 4)

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 871d
  Landau Jeffrey B was granted 30,000 shares, increasing direct ownership by 35% to 116,622 units (SEC Form 4)

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
• 871d
  Belvin Marcia was granted 26,250 shares, increasing direct ownership by 17% to 181,374 units (SEC Form 4)

  4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)

Other CTMX categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends